TC BioPharm (Holdings) plc (TCBWF)
US Markets
About TC BioPharm (Holdings) plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 2.0M | 3.8M | 0.00 | 0.00 |
| Operating Income | -7.3M | -12.1M | -14.2M | -12.8M |
| Net Income | -13.6M | -1.3M | -5.9M | -12.2M |